Allergen immunotherapy in China

Yaqi Yang; Wenjing Li; Rongfei Zhu

doi:10.3389/falgy.2023.1324844

Allergen immunotherapy in China

Front Allergy. 2024 Jan 8:4:1324844. doi: 10.3389/falgy.2023.1324844. eCollection 2023.

Authors

Yaqi Yang¹, Wenjing Li^#¹, Rongfei Zhu^#^{1

2}

Affiliations

¹ Department of Allergy, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
² Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.

^# Contributed equally.

Abstract

Allergen immunotherapy (AIT) is an etiological treatment strategy that involves administering escalating doses of clinically relevant allergens to desensitize the immune system. It has shown encouraging results in reducing allergy symptoms and enhancing patients' quality of life. In this review, we offer a thorough overview of AIT in China, examining its efficacy, safety, current practices, and prospects. We further underscore the progress made in AIT research and clinical applications, as well as the distinct challenges and opportunities that China faces in this area.

Keywords: adjuvant; allergen extracts; allergen immunotherapy; efficacy; safety.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article.